Home›Trial›NCT05681351
🔬NCT05681351Phase 3ACTIVE NOT RECRUITING

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

Study Summary

The purpose of this study is to evaluate the safety and tolerability of olezarsen in participants with SHTG.

Conditions
Severe Hypertriglyceridemia
Interventions / Drugs
Olezarsen
View on ClinicalTrials.gov ↗
Sponsor
IONS
Ionis Pharmaceuticals
Antisense Therapeutics
B68/100
Study Details
Enrollment885 participants
Primary Completion—
Lead SponsorIonis Pharmaceuticals, Inc.
Data Retrieved2026-04-11 04:17:53.139443+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.